Long-term results from the OLYMPIA open-label extension study show that nemolizumab (Nemluvio) provides durable efficacy and good tolerability for up to 3 years in patients with ...

The U.S. Food and Drug Administration has approved expanded use of Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency in adult and pediatric patients with a ...

Drug's approval expanded, but only to patients with genetic cerebral folate transport defi ...

Cerebral folate deficiency is a rare neurological disorder characterized by a decrease in CSF folate levels, leading to developmental regression, seizures, movement disorders, and other neurological ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for ...

The FDA approved leucovorin for cerebral folate deficiency linked to FOLR1 mutations but said evidence is insufficient to support approval for autism.

Among patients with moderate to severe atopic dermatitis, APG777 produced significant reductions in disease severity at 16 weeks.

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle• 3-hour incubation regimen ...

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...